Search

Your search keyword '"Polsky D"' showing total 565 results

Search Constraints

Start Over You searched for: Author "Polsky D" Remove constraint Author: "Polsky D"
565 results on '"Polsky D"'

Search Results

1. MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project

3. Noninvasive genomic detection of melanoma.

11. MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: A pooled analysis from the M-SKIP project

12. MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: A pooled analysis from the M-SKIP project

13. Cash Benchmarking For Integrated Health Care And Human Services Interventions: Finding The Value Added

18. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort

22. MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M‐SKIP project.

24. Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: A Pooled Analysis from the M-Skip Project

27. Chromatin Dynamics in Melanoma: A Role for MacroH2A

28. Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior

29. Genetic Determinants of Ipilimumab Outcomes for Advanced Melanoma

30. Il10 Locus As a Biomarker of Melanoma Survival

31. Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the 'gold standard'?

32. HMO growth and the geographical redistribution of generalist and specialist physicians, 1987-1997

33. A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates

35. Dermoscopy key points: recommendations from the international dermoscopy society

38. Agreement of Dermatopathologists in the Evaluation of Clinically Difficult Melanocytic Lesions: How Golden Is the ‘Gold Standard’?

40. Basal cell carcinoma: dermoscopy vascular features of different subtypes

48. Developing genetic markers for melanoma risk assessment

50. Phase II trial of sorafenib (S [BAY 43–9006]) in metastatic melanoma (MM) including detection of BRAF with mutant specific-PCR (MS-PCR) and altered proliferation pathways-final outcome analysis

Catalog

Books, media, physical & digital resources